Contraline CEO Kevin Eisenfrats holds up Echo-VR gel, a male contraceptive.
Source: The Associated Press
A cruel joke in the male contraceptives field is that a viable product has been "five years away" from market since the 1970s.
This time, though, medical-device developers say they may actually be five years away from commercializing a new male contraceptive.
As for when they might hit the market and be available for use? That could still be 10 years away, leaving condoms and vasectomies as the only male contraceptive options for now.
Innovators in the field of male contraceptives are "scrappy," small and underfunded, according to executives at Male Contraceptive Initiative, or MCI, which facilitates research and development of nonhormonal products to prevent pregnancy.
"Real developments are showing real promise making their way through the pipeline," said Logan Nickels, MCI's director of operations and programs. "And among the general public, these are things people want and will use — which was a case people had trouble making before."
Chart of the Week
Story: Male-contraceptive developers seek reproductive equity amid limited options
Story: Seasonality of cold, flu offers predictability of over-the-counter pharma sales
US House lawmakers take aim at surprise medical bills in new bipartisan effort
The Democratic and Republican heads of the House Energy and Commerce Committee have banded together to take action against surprise medical bills, in which Americans are increasingly confronted with unexpected, high out-of-pocket costs.
Gilead's Daniel O'Day defended the company's HIV drug Truvada on Capitol Hill at a May 16 hearing.
Source: The Associated Press
Gilead CEO defends HIV drug Truvada's price, insists CDC patents invalid
Daniel O'Day, the fairly new head of Gilead Sciences Inc., was on Capitol Hill to defend the price of his company's HIV drug Truvada and disputed allegations that anyone other than the California-based manufacturer had invented the medicine.
Pharma industry seeks drug pricing 'disruptors' to get back on track
At the Financial Times' Pharma & Biotech Summit on May 14 in New York City, business and regulatory leaders from the healthcare industry discussed "disruptors" in the industry that could shape it for years to come.
Of Mice Not Men: Treating Zika in mice; turning skin cells to stem cells; a fear, anxiety gene
Researchers turn to an already-approved rheumatoid arthritis drug to treat Zika-related birth defects, a new gene mutation could reduce fear and anxiety, and genes that may transform skin cells into embryos.
Stakeholders weigh in on direction for US FDA biosimilar insulin pathway
Drugmakers, patients and other stakeholders weighed in on whether U.S. regulators should treat products intended to be lower-cost versions of insulins any differently in the approval process than cheaper forms of complex biologic medicines.In Other News
Johnson & Johnson expects pharma division to surpass $50B in sales by 2023
Johnson & Johnson CFO Joe Wolk said at the company's latest business review on May 15 that its pharmaceutical arm is expected to rise "comfortably above" $50 billion in sales by 2023 on the back of new products and a wide range of volume-driven growth.
Trump administration drops proposal to let Medicare plans exclude certain drugs
The Trump administration backed away from a key part of its proposal to let Medicare drug plans restrict coverage of certain medicines — a retreat that could upend other parts of its strategy to lower the costs of prescription therapies in the U.S.
Gottlieb slams drug import idea; Trump backs actions on surprise medical bills
Former U.S. Food and Drug Administration Commissioner Scott Gottlieb criticized efforts by his former bosses to potentially let states import medicines. Also, the White House backed legislative efforts to rein in surprise medical bills.
Witnesses: Health effects of climate change costly; seniors, young hit hardest
The health effects of climate change are costly and are not only imperiling Americans' well-being but the nation's ability to pay for care and other needs, like improving the U.S. infrastructure, witnesses told a House committee.
UK's Wellcome Trust launches snakebite fund
The U.K.'s Wellcome Trust has unveiled an £80 million program to improve the treatment of snakebites, which are responsible for more deaths than any other tropical disease and equal to those caused by prostate and cervical cancer.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.